NCT00267514View on ClinicalTrials.gov

Study to Demonstrate Equivalence of Sevelamer Carbonate Powder and Sevelamer HCl Tablets in Haemodialysis Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

March 31, 2007

Study Completion Date

May 31, 2007

Conditions
Chronic Kidney Disease
Interventions
DRUG

sevelamer carbonate (Renvela®) sevelamer hydrochloride (Renagel ®)

sevelamer carbonate powder dosed TID with meals for four weeks followed by sevelamer hydrochloride tablets dosed TID with meals for four weeks

DRUG

sevelamer hydrochloride (Renagel ®) sevelamer carbonate (Renvela®)

sevelamer hydrochloride tablets dosed TID with meals for four weeks followed by sevelamer carbonate powder dosed TID with meals for four weeks

Trial Locations (7)

BS10 5NB

Southmead Hospital, Bristol

CB2 2QQ

Addenbrooks NHS Trust, Cambridge

E1 1BB

The Royal London Hospital, London

SE1 9RT

Guy's Hospital, London

M13 9WL

Manchester Royal Infirmary, Manchester

M6 8HD

Hope Hospital, Manchester

NR4 7UY

Norfolk and Norwich University Hospital, Norwich

All Listed Sponsors
lead

Genzyme, a Sanofi Company

INDUSTRY

NCT00267514 - Study to Demonstrate Equivalence of Sevelamer Carbonate Powder and Sevelamer HCl Tablets in Haemodialysis Patients | Biotech Hunter | Biotech Hunter